Fundz

Amprion reported raising $11 Million in an initial SEC Form D filing, from an offering of $11 Million

PRIVATEJul 15, 2022

Amount Raised

$11 Million

$11 Million sold, per SEC Form D (first sale Jun 24, 2022)

Round Type

Venture

San FranciscoBiotechnology

Quick answer

Amprion raised $11 Million in a funding round, dated June 24, 2022. Amprion is based in San Francisco, California, United States.

How much did Amprion raise?
Amprion raised $11 Million in a funding round on June 24, 2022.
What does Amprion do?
Amprion is a global leader advancing precision medicine for neurodegenerative disorders through seed amplification testing.
Where is Amprion based and how big is it?
Amprion is based in San Francisco, California, United States. Fundz records about 38 employees.
Who are the decision-makers at Amprion?
Fundz holds 2 contacts at Amprion, including the Chief Commercial Officer. Names and contact details are shown to Fundz members.

Source: Fundz verified event record.

Who else raised in Biotechnology around the same time

Companies in the same sectors as Amprion that raised within 45 days of this round, from Fundz verified event records.

  • Innervace raised $10M on August 8, 2022.
  • Avinger Inc raised $2.4M (Seed) on August 8, 2022.
  • Eyestem raised an undisclosed amount (Funding Round) on August 8, 2022.
  • Nortis Inc raised $6M on August 8, 2022.
  • Skylark Bio raised $23M on August 8, 2022.
  • Epigenic Therapeutics raised $20M (Series A) on August 6, 2022.

Who to call at Amprion, and when

A new round usually means Amprion is about to hire and buy. The teams that reach out first get the meeting.

  • An alert the day Amprion raises, hires an executive or expands, scored against what you sell
  • The decision-makers there, with verified emails
  • Who you already know at Amprion, from your own LinkedIn network

Works inside ChatGPT and Claude. Ask who to call at Amprion. With Fundz connected, it knows.

Watch Fundz in
See plan options
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce 4.8/5 on G2

Company Information

Company

Amprion

Location

149 NEW MONTGOMERY STREET, 4TH FLOOR

San Francisco, California, United States

About

Amprion is a global leader advancing precision medicine for neurodegenerative disorders through seed amplification testing. Amprion’s SAAmplify™-ɑSYN (formerly SYNTap®) Biomarker Test is a first-in-class, qualitative Laboratory Developed Test (LDT) and the only seed amplification assay available to aid the diagnosis of synucleinopathies such as Parkinson’s disease (PD), Lewy body dementia (LBD/DLB), and Alzheimer’s disease (AD) with Lewy body variant.

AI made execution free. Knowing first is the whole game now.

Fundz sees it the moment Amprion raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.

Related People

2 contacts
Verified contactsBrandt, Chief Commercial Officer hidden hiddenSee plans and pricing
Predictive Intelligence
Strategic

ML-powered predictions for Amprion's next move

See what Strategic adds

Amprion raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 281,000+ organizations. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.